An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer

por Thiery-Vuillemin, A., Fizazi, K., Sartor, O., Oudard, S., Bury, D., Thangavelu, K., Ozatilgan, A., Poole, E.M., Eisenberger, M., de Bono, J.
Publicado 2021

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

por Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N. J., Coleman, R. E., O'Sullivan, J. M., Reuning-Scherer, J., Shan, M., Zhan, L., Parker, C.
Publicado 2016

Advances in targeted alpha therapy for prostate cancer

por De Vincentis, G, Gerritsen, W, Gschwend, J E, Hacker, M, Lewington, V, O’Sullivan, J M, Oya, M, Pacilio, M, Parker, C, Shore, N, Sartor, O
Publicado 2019

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

por Sartor, O., Coleman, R. E., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Vogelzang, N. J., Bruland, Ø., Kobina, S., Wilhelm, S., Xu, L., Shan, M., Kattan, M. W., Parker, C.
Publicado 2017

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or i...

por Petrylak, D.P., Vaishampayan, U.N., Patel, K.R., Higano, C.S., Albany, C., Dawson, N.A., Mehlhaff, B.A., Quinn, D.I., Nordquist, L.T., Wagner, V.J., Siegel, J., Trandafir, L., Sartor, O.
Publicado 2021

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases

por Sartor, O., Heinrich, D., Mariados, N., Méndez Vidal, M. J., Keizman, D., Thellenberg Karlsson, C., Peer, A., Procopio, G., Frank, S. J., Pulkkanen, K., Rosenbaum, E., Severi, S., Trigo Perez, J. M., Wagner, V., Li, R., Nordquist, L. T.
Publicado 2017

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

por Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., Soule, H. R., Akaza, H., Beer, T. M., Beltran, H., Chinnaiyan, A. M., Daugaard, G., Davis, I. D., De Santis, M., Drake, C. G., Eeles, R. A., Fanti, S., Gleave, M. E., Heidenreich, A., Hussain, M., James, N. D., Lecouvet, F. E., Logothetis, C. J., Mastris, K., Nilsson, S., Oh, W. K., Olmos, D., Padhani, A. R., Parker, C., Rubin, M. A., Schalken, J. A., Scher, H. I., Sella, A., Shore, N. D., Small, E. J., Sternberg, C. N., Suzuki, H., Sweeney, C. J., Tannock, I. F., Tombal, B.
Publicado 2015